ArticleOncotarget2016

Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.

Joost H van Ginkel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.